Archives
-
Methyl-β-cyclodextrin: Membrane Workflow Guide
2026-09-02
Methyl-β-cyclodextrin (methyl beta cyclodextrin) is a soluble biochemical reagent for controlled cholesterol and lipid extraction from cell membranes, supporting membrane fluidity modulation and studies of lipid organization. It is intended for scientific research workflows only, not diagnostic or medical use, and solutions should be prepared close to the experiment rather than stored long term.
-
NSP15 Inhibitor Screening: Thymopentin and Oleuropein
2026-09-02
The reference study used structure-based virtual screening and molecular dynamics simulations to identify thymopentin and oleuropein as high-priority natural-product binders of the SARS-CoV-2 NSP15 endoribonuclease. Its main contribution is a computational framework for prioritizing candidates against an immune-evasion factor, while the absence of biochemical and cellular validation means the compounds remain research hypotheses rather than confirmed antivirals.
-
Alpha-Ketoglutarate Workflows for Tumor Metabolism
2026-09-01
Build reproducible alpha-ketoglutarate assays that connect TCA-cycle flux, PDHA1 activity, and macrophage antigen presentation. This practical workflow separates direct metabolite effects from PDHA1-succinylation biology and adds controls for solubility, uptake, and chemotherapy-sensitization studies.
-
ATP Solution (100 mM) for mRNA and Kinase Workflows
2026-09-01
ATP Solution is a ready-to-use 100 mM aqueous source of Adenosine-5'-triphosphate for phosphate-transfer and RNA-synthesis workflows. Its documented pH, HPLC purity, nuclease and phosphatase controls, and frozen-storage guidance support reproducible kinase, transcription, ligation, and phosphorylation assays.
-
EZ Cap™ Firefly Luciferase mRNA Workflow
2026-08-31
Build more interpretable mRNA delivery, translation, and reporter workflows with a Cap1/poly(A)-optimized firefly luciferase transcript. This guide connects cell-based assay design with lipid nanoparticle comparison, in vivo bioluminescence imaging, and practical troubleshooting.
-
H-89: PKA Logic in Wnt-Driven Bone Formation
2026-08-31
H-89 offers a practical way to interrogate the cAMP–PKA branch of Wnt-driven osteogenic signaling. This thought-leadership guide connects pharmacologic PKA inhibition with O-GlcNAcylation, glycolytic rewiring, assay design, and translational decision-making.
-
Corin Triggers Cuproptosis in Liver Cancer
2026-08-30
The reference study identifies Corin as a dual KDM1A/HDAC1 inhibitor that suppresses hepatocellular carcinoma cell growth and links this activity to FDX1-associated cuproptosis. Its screening-to-mechanism workflow illustrates how a CCK-8-based phenotypic assay can help prioritize epigenetic compounds for mechanistic cancer research, while also highlighting the need for validation beyond a limited cell-line panel.
-
H-Aggregated NIR-II Fluorophore for Cancer Therapy
2026-08-29
Yu et al. developed an RR9-functionalized liposome that transfers H-aggregated IR-1061 from the carrier to tumor cell membranes, combining NIR-II fluorescence imaging with more persistent photothermal therapy. Loading carboplatin added temperature-sensitive chemotherapy, producing a lipid nanosystem for image-guided thermochemotherapy while highlighting membrane-state engineering as a design strategy.
-
JNJ-10198409: PDGF Receptor Inhibitor
2026-08-28
JNJ-10198409 is a nanomolar platelet-derived growth factor receptor inhibitor for dissecting PDGF-BB-driven proliferation, tumor–stroma signaling, and angiogenesis-associated phenotypes. This guide turns its ATP-competitive mechanism and practical solubility profile into staged, quantitative workflows with controls for pathway specificity and assay robustness.
-
Engineering mRNA That Performs: From Tail to Therapy
2026-08-28
Polyadenylation is more than a finishing step in mRNA engineering: it is a controllable design variable that can influence RNA persistence, translation, and experimental reproducibility. This thought-leadership analysis connects the HyperScribe™ Poly (A) Tailing Kit with findings from NGFR100W mRNA delivery research and outlines a practical path from in vitro transcription RNA modification to translational validation.
-
Enhanced ECL Detection for BMSC Protein Studies
2026-08-27
Discover how the ECL Chemiluminescent Substrate Detection Kit supports sensitive, reproducible protein immunodetection in BMSC toxicology studies. This article connects pathway-focused western blot design with practical decisions for phosphoprotein measurement, imaging, and assay validation.
-
Z-YVAD-FMK in Caspase-1 Pyroptosis Assays
2026-08-27
Use Z-YVAD-FMK to distinguish caspase-1-dependent pyroptosis from apoptosis, inflammasome-associated signaling, and unrelated forms of cell death. This workflow combines dose-controlled inhibition with GSDMD, cytokine, viability, and caspase-3 readouts for stronger cancer research conclusions.
-
Nitric Oxide Nanomotors for Glioblastoma Immunotherapy
2026-08-26
The reference study develops a chemotactic nanomotor that uses the reactive glioblastoma microenvironment to improve brain-tumor localization and coordinate antitumor immune responses. Its angiopep-2 and mitochondria-targeted lonidamine design links blood–brain barrier transport, tumor-cell killing, immunogenic cell death, and immune memory in one delivery strategy.
-
LNP–mRNA Delivery in Pregnancy: Structure and Route
2026-08-26
This PNAS study shows that lipid nanoparticle composition and administration route jointly determine mRNA expression, inflammation, and maternal–fetal outcomes in pregnant mice. Its mechanistic findings provide a framework for separating delivery potency from immunological risk when designing pregnancy-relevant RNA therapies and reporter workflows.
-
PDHA1 Succinylation and α-KGA in Cholangiocarcinoma
2026-08-25
A 2025 Nature Communications study identifies a PDHA1 K83 succinylation–α-KGA–OXGR1 signaling axis that connects cholangiocarcinoma metabolism with impaired macrophage antigen presentation. The findings provide a mechanistic explanation for immune escape and suggest that targeting this metabolic post-translational modification may improve gemcitabine–cisplatin responses in preclinical models.